BANK VONTOBEL/PUT/ROCHE GS/260/0.1/20.09.24

BANK VONTOBEL/PUT/ROCHE GS/260/0.1/20.09.24 Stock

DE000VM3V489

Delayed Deutsche Boerse AG 14:06:19 2024-06-28 EDT
1.53 ^EUR	+3.38%

Current month	-51.27%
1 month	-53.92%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ROCHE HOLDING AG

Chart BANK VONTOBEL/PUT/ROCHE GS/260/0.1/20.09.24

Latest news about ROCHE HOLDING AG

BioPharma Credit to Provide Additional Funding to LumiraDx Amid Roche Deal	03:20am	MT
Swiss Market Index Closes Little Changed Amid Key European Inflation Data	06-28	MT
Roche's Eye Therapy Vabysmo Gets EU Panel's Nod for Additional Indication	06-28	MT
Roche: positive CHMP opinion for Vabysmo in OVR	06-28	CF

More news

Quotes 5-day view

Date	Price	Change
24-06-28	1.53	+3.38%
24-06-27	1.48	-3.90%
24-06-26	1.54	+24.19%
24-06-25	1.24	+4.20%
24-06-24	1.19	-11.85%

Delayed Quote Deutsche Boerse AG

Last update June 28, 2024 at 02:06 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	ROCHE HOLDING AG
Issuer	Vontobel
WKN	VM3V48
ISIN	DE000VM3V489
Date issued	2023-10-11
Strike	260 CHF
Maturity	2024-09-20 (82 Days)
Parity	10 : 1
Emission price	2.38 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	4.76 €
Lowest since issue	1.18 €
Delta	-0.65x
Omega	11.14
Premium	1.71x
Gearing	17.26x
Moneyness	1.041
Difference Strike	9.7 CHF
Difference Strike %	+3.73%
Spread	0.01 €
Spread %	0.67%
Intrinsic value	1.090

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

More about the company

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Consensus: Roche Holding AG

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

249.5 CHF

Average target price

278.1 CHF

Spread / Average Target

+11.44%

Consensus